Trial Profile
Phase I/II Dose-escalation Study of the Investigational Trifunctional Bispecific Anti-CD20 x Anti-CD3 Antibody FBTA05 in Combination With Donor Lymphocyte Infusion (DLI) in Patients With CD20 Positive Chronic Lymphocytic Leukemia (CLL), Low and High Grade Non-Hodgkins Lymphoma (NHL) After Allogeneic Stem Cell Transplantation.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 09 Dec 2022
Price :
$35
*
At a glance
- Drugs FBTA 05 (Primary) ; T cell replacement therapy
- Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms STP-LYM-01
- 05 Dec 2022 Planned End Date changed from 1 Jun 2016 to 1 Jun 2015.
- 05 Dec 2022 Planned primary completion date changed from 1 May 2016 to 1 May 2015.
- 05 Dec 2022 Status changed from discontinued to withdrawn prior to enrolment.